No Mention of Breyanzi or Cilta-cel in July’s CHMP Agenda; Will Abecma be Approved Before September?
On Monday, July 19, the CHMP agenda for July was released. Of note, no major updates were observed for Breyanzi (BMS), or cilta-cel (JNJ / Legend). Below, Celltelligence provides likely EU approval timelines for Abecma, Breyanzi, and cilta-cel.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.